Vir Biotechnology provided key program updates, including positive data from the ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta (CHD).
New Phase 1 data from PSMA-targeted PRO-XTEN ® dual-masked T-cell engager VIR-5500 in prostate cancer will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in February.
Year-end 2025 cash and investments balance of approximately $781M with extended cash runway into Q4 2027.
Phase 2 SOLSTICE Data
88% of chronic hepatitis delta participants achieved undetectable HDV RNA at Week 96 with combination therapy of tobevibart and elebsiran.
VIR-5500 Presentation
Safety and efficacy data from the Phase 1 trial of VIR-5500 in prostate cancer will be shared at the 2026 ASCO Genitourinary Cancers Symposium.
Financial Update
Cash and investments balance at year-end 2025 was approximately $781M with cash runway extended into Q4 2027.
- The combination therapy of tobevibart and elebsiran showed promising results in achieving undetectable viral load in a large number of chronic hepatitis delta patients.
- Safety and efficacy data sharing at medical conferences like ASCO enhances transparency and credibility for Vir Biotechnology.
- Financial stability with a cash balance of $781M by the end of 2025 provides a strong foundation for continued research and development activities.
Vir Biotechnology's latest updates reflect significant progress in its programs for chronic hepatitis delta and oncology, showcasing promising data and financial stability for future growth and innovation.